Lobna Ali
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Lobna Ali has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
Alexandra Chetty
Section of General Internal Medicine, Department of Internal Medicine, LSU Health Sciences Center School of Medicine in New Orleans New Orleans Louisiana USA
1 shared publication- Audrey Marsh
Section of General Internal Medicine, Department of Internal Medicine, LSU Health Sciences Center School of Medicine in New Orleans New Orleans Louisiana USA
1 shared publication - Cynthia J. Brown
Department of Internal Medicine Louisiana State University School of Medicine New Orleans Louisiana USA
1 shared publication Erwin Aguilar
Section of Geriatric Medicine, Department of Internal Medicine, LSU Health Sciences Center School of Medicine in New Orleans New Orleans Louisiana USA
1 shared publication- Julijana Conic
Section of Geriatric Medicine, Department of Internal Medicine, LSU Health Sciences Center School of Medicine in New Orleans New Orleans Louisiana USA
1 shared publication Lily Chen
Section of General Internal Medicine, Department of Internal Medicine, LSU Health Sciences Center School of Medicine in New Orleans New Orleans Louisiana USA
1 shared publication
Latest Publications
- Open Access
- 18 February 2025
- Published by Wiley in Aging Medicine
- Vol. 8 (1)
Effect of Steroids on the Progression of Alzheimer's Dementia: A Retrospective Chart Review
Objectives: Alzheimer's disease (AD) is a prevalent age‐related neurodegenerative disease that affects millions of individuals in the United States. Neuroinflammation is a driver of the neurodegenerative changes that characterize AD, prompting interest in how inflammation can be modulated for treatment and prevention.Methods: ICD‐10 codes were quarried from electronic medical records to identify patients diagnosed with AD from 2012 to 2020. The patients were then divided into those who used systemic steroids and those who did not before the progression of their disease. Data on medication prescribed was used to measure the disease's progression. Clinical findings and laboratory results were collected to build a propensity score. Patients were followed until disease progression, death, or the last available visit. Kaplan–Meier curves and hazard ratios adjusted for the propensity score were used to compare the two groups.Results: Of the 459 patients identified, 77 were included in the study, and 13 used steroids. Of the 77 patients included in the study, 59 had progression of their disease, and of those, five used steroids. The median time to progression was 408.00 (191.00, 979.00) days for the overall sample. The hazard ratio (HR) comparing the group using steroids to those not using steroids was 0.26 with a 95% CI of (0.1013, 0.673) and a p value of 0.00064.Conclusions: In our study, steroid use delayed the progression of dementia. Further study is needed to outline how steroids and anti‐inflammatory medications can be used in the treatment and prevention of AD.
- 18 February 2025
- Published by Wiley in Aging Medicine
- Vol. 8 (1)
Open AccessEffect of Steroids on the Progression of Alzheimer's Dementia: A Retrospective Chart Review
Objectives: Alzheimer's disease (AD) is a prevalent age‐related neurodegenerative disease that affects millions of individuals in the United States. Neuroinflammation is a driver of the neurodegenerative changes that characterize AD, prompting interest in how inflammation can be modulated for treatment and prevention.Methods: ICD‐10 codes were quarried from electronic medical records to identify patients diagnosed with AD from 2012 to 2020. The patients were then divided into those who used systemic steroids and those who did not before the progression of their disease. Data on medication prescribed was used to measure the disease's progression. Clinical findings and laboratory results were collected to build a propensity score. Patients were followed until disease progression, death, or the last available visit. Kaplan–Meier curves and hazard ratios adjusted for the propensity score were used to compare the two groups.Results: Of the 459 patients identified, 77 were included in the study, and 13 used steroids. Of the 77 patients included in the study, 59 had progression of their disease, and of those, five used steroids. The median time to progression was 408.00 (191.00, 979.00) days for the overall sample. The hazard ratio (HR) comparing the group using steroids to those not using steroids was 0.26 with a 95% CI of (0.1013, 0.673) and a p value of 0.00064.Conclusions: In our study, steroid use delayed the progression of dementia. Further study is needed to outline how steroids and anti‐inflammatory medications can be used in the treatment and prevention of AD.
- 24 April 2024
- Published by Springer Nature
- p. 131-144
Promoting Mobility in the Acute Care Setting